Research programme: systemic lupus erythematosus therapy - TanoxAlternative Names: Systemic lupus erythematosus therapy research programme - Tanox; TNX-668
Latest Information Update: 04 May 2007
At a glance
- Originator Tanox
- Mechanism of Action Cytokine modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Systemic lupus erythematosus
Most Recent Events
- 04 May 2007 No development reported - Preclinical for Systemic lupus erythematosus in USA (unspecified route)
- 18 Jan 2005 Preclinical trials in Systemic lupus erythematosus in USA (unspecified route)